LINC02551: A Drug Target / Disease Biomarker (G100507431)

Target Name: LINC02551

NCBI ID: G100507431

LINC02551

Other Name(s): long intergenic non-protein coding RNA 2551 | RP11-890B15.3 | RP11-890B15.2 | Uncharacterized LOC100507431

LINC02551: A Drug Target / Disease Biomarker

LINC02551 is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. It is a key regulator of the cell cycle and is involved in the development and progression of various diseases, including cancer.

LINC02551 is a small non-coding RNA molecule that is approximately 200 nucleotides in length. It is produced by RNA polymerase II and is found in various tissues and cells throughout the body. LINC02551 is a key regulator of the cell cycle, and it is involved in the development and progression of various diseases, including cancer.

One of the key functions of LINC02551 is to regulate the cell cycle. The cell cycle is the process by which a cell grows, replicates its DNA, and divides. LINC02551 is involved in the regulation of the G1 phase of the cell cycle, which is the phase of the cell cycle when the cell prepares for cell division. During the G1 phase, LINC02551 helps to ensure that the cell has enough copies of its DNA and RNA to begin cell division.

Another function of LINC02551 is to regulate the expression of genes. LINC02551 interacts with various transcription factors, which are proteins that help to regulate the expression of genes. LINC02551 helps to ensure that these transcription factors have access to the mRNA they need to transcript into proteins. This interaction between LINC02551 and transcription factors is important for the regulation of various cellular processes, including cell growth, differentiation, and disease development.

In addition to its functions in regulating the cell cycle and the expression of genes, LINC02551 is also involved in the development and progression of various diseases, including cancer. Cancer is a disease in which cells divide out of control, leading to the formation of tumors. LINC02551 is thought to be involved in the regulation of cell division and may be a potential drug target or biomarker for cancer.

One potential mechanism by which LINC02551 may be involved in cancer development is by regulating the activity of oncogenes, which are genes that promote the growth and division of cancer cells. Oncogenes are often mutated in cancer, and LINC02551 may help to prevent or reverse these mutations. Additionally, LINC02551 may also be involved in the regulation of apoptosis, which is the process by which cells die and are removed from the body in response to various stimuli. Disruptions in apoptosis have been implicated in the development and progression of cancer.

Another potential mechanism by which LINC02551 may be involved in cancer development is by regulating the production of cellular signaling molecules. Many signaling molecules are produced by cells in response to various stimuli, and they play important roles in the regulation of cellular processes, including cell growth, differentiation, and survival. LINC02551 may be involved in the regulation of the production of these signaling molecules, and disruptions in these processes may contribute to the development and progression of cancer.

In conclusion, LINC02551 is a non-coding RNA molecule that is involved in the regulation of the cell cycle and the expression of genes. It is also thought to be involved in the development and progression of various diseases, including cancer. Further research is needed to fully understand the role of LINC02551 in these processes and to determine its potential as a drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2551

The "LINC02551 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02551 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets